Unable to Reach Licensing Deal, Rosetta Genomics Will Not Receive $1.25M Payment | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Unable to reach a licensing deal with a lender, Rosetta Genomics will not receive a $1.25 million payment, the company disclosed in a document filed with the US Securities and Exchange Commission today.

Rosetta and the unnamed lender had agreed to negotiate for the licensing deal as part of a $1.75 million private placement raise that Rosetta announced in late January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.